METHOD OF TREATING GASTRIC AND/OR DUODENAL ULCER Russian patent published in 2014 - IPC A61K38/21 A61P1/04 A61K33/06 

FIELD: medicine.

SUBSTANCE: human recombinant interferon alpha-2b is orally administered into a patient's body as an ingredient of an anti-acid protective medium in a dose of 500 thousand IU twice a day for at least 7 days. The length of the therapeutic course is no more than 14 days. As human recombinant interferon alpha-2b, the preparation contains Reaferon-EC or Reaferon-EC-Lipint; as the anti-acid protective medium, the preparation contains aluminium hydroxide and magnesium hydroxide in the following quantitative ratio: aluminium hydroxide - 25-35 mg/ml; magnesium hydroxide - 15-30 mg/ml; human recombinant interferon alpha-2b - 0.35·105-5·105 IU/ml.

EFFECT: using the given method enables providing higher clinical effectiveness in gastric or duodenal ulcer in a combination with reducing the content of human recombinant interferon alpha-2b in 4 times in a single dose, and in 2 times in a daily dose that is ensured by the preparation delivery directly into the ulcer.

3 cl, 1 tbl, 2 ex